Lytix Biopharma AS (OSL: LYTIX)

Market Cap	284.76M
Revenue (ttm)	10.76M
Net Income (ttm)	-80.92M
Shares Out	49.61M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55,769
Average Volume	533,809
Open	5.86
Previous Close	5.76
Day's Range	5.74 - 5.90
52-Week Range	5.10 - 15.00
Beta	-0.61
RSI	40.53
Earnings Date	Feb 13, 2025

About Lytix Biopharma AS

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company’s products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 8
• Stock Exchange: Oslo Børs
• Ticker Symbol: LYTIX

Financial Performance

In 2023, Lytix Biopharma AS's revenue was 3.99 million, a decrease of -63.82% compared to the previous year's 11.03 million. Losses were -87.90 million, 56.8% more than in 2022.